Page last updated: 2024-12-10

dothiepin hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dothiepin: A tricyclic antidepressant with some tranquilizing action. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5282426
CHEMBL ID108947
CHEBI ID36802
CHEBI ID36798
SCHEMBL ID34482
MeSH IDM0331397
PubMed CID9884029
CHEMBL ID1711280
SCHEMBL ID35428
MeSH IDM0331397

Synonyms (96)

Synonym
AC-16702
CHEBI:36802 ,
(3z)-3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethylpropan-1-amine
cis-dothiepin
3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethylpropan-1-amine
n,n-dimethyldibenzo[b,e]thiepin-delta(11(6h),gamma)-propylamine
3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethyl-1-propanamine
CHEBI:36798
prothiadene hydrochloride
prothiaden hydrochloride
(3z)-3-(6h-benzo[c][1]benzothiepin-11-ylidene)-n,n-dimethyl-propan-1-amine
prothiadiene
nsc172130
n-(3-dibenzo[b,e]thiepin-11(6h)-ylidenepropyl)-n,n-dimethylamine
dothiepin
3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethyl-1-propanamine, (3z)-
PRESTWICK2_000488
L001095
CHEMBL108947
D07872
dothep (tn)
dosulepin (inn)
(3z)-3-(6h-benzo[c][1]benzothiepin-11-ylidene)-n,n-dimethylpropan-1-amine
cas_897-15-4
nsc_3155
bdbm82548
AKOS015962346
gtpl7549
SCHEMBL34482
dosulepin, z-isomer
dothiepin, z-isomer
25627-38-7
unii-cz377vwx9p
dothiepin, z-
(z)-n,n-dimethyl-3-(6,11-dihydrodibenzo(b,e)thiepin-11-ylidene)propylamine
cz377vwx9p ,
1-propanamine, 3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethyl-, (3z)-
dosulepin hydrochloride impurity e [ep impurity]
J-002986
(z)-3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethyl-1-propanamine
DTXSID90873548
z-dothiepin
Q598713
Q27116967
med.21724, compound 193
bdbm429518
n,n-dimethyl- dibenzo[b,e]thiepin-11(6h),gamma-propylamine
dimethyl({3-[(2z)-9-thiatricyclo[9.4.0.0?,?]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene]propyl})amine
unii-3h0042311v
3h0042311v ,
smr001233202
MLS002153839
idom
dibenzo(b,e)thiepin-delta(sup 11(6h),gamma)-propylamine, n,n-dimethyl-, hydrochloride
n,n-dimethyldibenzo(b,e)thiepin-delta(sup 11(6h),gamma)-propylamine hydrochloride
1-propanamine, 3-dibenzo(b,e)thiepin-11(6h)-ylidene-n,n-dimethyl-, hydrochloride
xerenal
dibenzo(b,e)thiepin-delta(sup 11(6h),gamma)-propylamine, n,n-dimethyl-, hydrochloride, (e)-
dibenzo(b,e)thiepin-delta11(6h),gamma-propylamine, n,n-dimethyl-, hydrochloride
dothiepin hydrochloride [usan]
11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepine hydrochloride
einecs 212-978-8
nsc 172130
depresym
nsc-172130
11-[3-(dimethylamino)propylidene]-6,e]thiepine hydrochloride
wln: t c676 is&t&j b3n1&1 &gh
1-propanamine,e]thiepin-11(6h)-ylidene-n,n-dimethyl-, hydrochloride
11-[3-(dimethylamino)propylidene]-6,e]thiepin hydrochloride
n,e]thiepin-.delta.11(6h),.gamma.-propylamine, hydrochloride
dibenzo[b,.gamma.-propylamine, n,n-dimethyl-, hydrochloride
dothiepin hcl
dopress
CHEMBL1711280
dosulepin hydrochloride [who-dd]
dosulepin hydrochloride [jan]
dosulepin hydrochloride [ep monograph]
dothiepin hydrochloride [mi]
dosulepin hydrochloride [mart.]
thaden
CCG-220488
SCHEMBL35428
1-propanamine, 3-dibenzo[b,e]thiepin-11(6h)-ylidene-n,n-dimethyl-, hydrochloride, (e)-
SR-01000838836-2
sr-01000838836
dothiepin hydrochloride (dosulepin hydrochloride) 1.0 mg/ml in methanol (as free base)
dothiepin hydrochloride; dosulepin hydrochloride
(3e)-3-(dibenzo[b,e]thiepin-11(6h)-ylidene)-n,n-dimethylpropan-1-amine, hydrogen chloride (1:1)
DTXSID60873550
dothiepinhcl
BD164382
Q27116969
AMY40796
dothiepin hydrochloride- bio-x
dothiepin.hcl (cis/trans)
dothiepin.hcl (cis/trans), 1mg/ml in methanol

Research Excerpts

Overview

Dothiepin hydrochloride is a well-established and effective antidepressant in patients with depressive symptoms of varying severity and co-existing anxiety.

ExcerptReferenceRelevance
"Dothiepin hydrochloride is a well-established and effective antidepressant in patients with depressive symptoms of varying severity and co-existing anxiety."( Evaluation of efficacy and tolerability of dothiepin hydrochloride in the management of major depression in patients suffering from rheumatoid arthritis.
Bhagat, V; Borges, NE; Dhavale, HS; Durge, V; Gawande, S; Kini, S; Londhe, V; Nadkar, MY, 2005
)
1.31

Toxicity

ExcerptReferenceRelevance
" However, this theory cannot be rejected as the mechanisms causing toxic hepatitis from tricyclic and tetracyclic antidepressants may well differ."( [Possible cross hepatotoxicity between tricyclic and tetracyclic antidepressive agents].
Quedens, JH; Rasmussen, S, 1991
)
0.28
" It is a safe and effective agent for the treatment of major depressive disorder."( Dothiepin hydrochloride: treatment efficacy and safety.
Blanchard, C; Elliot, C; Lou, P; Manschreck, TC; Rosenbaum, J; Zusky, P, 1986
)
1.71
"Selective serotonin reuptake inhibitors (SSRIs) and venlafaxine have been regarded as less toxic in overdose than tricyclic antidepressants (TCAs)."( Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.
Buckley, NA; Dawson, AH; Whyte, IM, 2003
)
0.32
" The aim of this study was to investigate antidepressant prescribing patterns, and selected adverse events in patients prescribed dosulepin following introduction of the NPI."( Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales.
Bracchi, RC; Chaplin, K; Deslandes, PN; Haines, KE; Routledge, PA, 2023
)
0.91
" During follow-up, recorded incidence of selected adverse events was low across all groups and no significant difference was observed."( Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales.
Bracchi, RC; Chaplin, K; Deslandes, PN; Haines, KE; Routledge, PA, 2023
)
0.91
" This study provides some reassurance that dosulepin discontinuation can be a successful strategy, and that the risk of the adverse events investigated was unlikely to have been greater in those who had dosulepin discontinued than in those in whom dosulepin had been continued."( Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales.
Bracchi, RC; Chaplin, K; Deslandes, PN; Haines, KE; Routledge, PA, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"1 L/h as the dose was increased from 50 to 150 mg, but there was no significant effect on the terminal half-life (approximately 20 h)."( Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study.
Dimmitt, DC; Giesing, DH; Lanman, RC; Yu, DK, 1986
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control."( Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.
De Laat, M; Devulder, J; Dumoulin, K; Renson, A; Rolly, G, 1996
)
0.29

Dosage Studied

Three rapid, simple, reproducible and sensitive extractive colorimetric methods (A--C) were investigated. The proposed methods were successfully applied for the determination of dothiepin hydrochloride in bulk powder and in capsule dosage form.

ExcerptRelevanceReference
"Five healthy volunteers took part in a crossover study which examined the serum concentrations of dothiepin and northiaden after a 25 mg three times a day and a 75 mg once a day dosage regimen of Prothiaden."( Steady-state serum concentrations of dothiepin and northiaden after two dosage regimens of dothiepin hydrochloride (Prothiaden).
Glass, RC; Nakra, BR; Rees, JA, 1977
)
0.48
" The dosage required was between 75 and 225 mg/day with 75% of patients receiving between 125 and 150 mg/day."( A retrospective assessment of the long-term effects of dothiepin.
Herridge, CF, 1975
)
0.25
" Furthermore, the SSRIs generally do not require dosage escalation for most patients and evidence indicates that they are effective in the treatment of depression associated with anxiety and insomnia."( Bridging the gap between psychiatric practice and primary care.
Thompson, C, 1992
)
0.28
" It is concluded that at least in the dosage schedule used herein, dothiepin does not influence hypoalgesia of diabetic neuropathy."( Effect of dothiepin on nociceptive response in diabetic rats.
Andrade, C; David, J; Rani, MA, 1992
)
0.28
" The dosage of both drugs was 50 mg nocte for three days, 100 mg nocte for the remainder of the first week, thereafter increasing to a maximum of 200 mg/day according to response/tolerance."( A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients.
Akhtar, MJ; Ashford, JJ; Kellett, JM; Rahman, MK; Savla, NC; Sharma, RR, 1991
)
0.28
" Dothiepin and amitriptyline were both given at a dosage of 75 mg daily for the 1st week; this was then increased to 150 mg and 100 mg, respectively, for the final 5 weeks of the study."( The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline.
Blacker, R; Chapman, N; Davey, A; Shanks, NJ, 1988
)
0.27
" More cautions dosage regimens of these drug should be considered for elderly patients."( Age differences in effects on blood pressure, flicker fusion frequency, salivation and pharmacokinetics of single oral doses of dothiepin and amitriptyline.
Hazama, H; Honma, H; Kawahara, K; Kishimoto, A; Mizukawa, R; Ogura, C, 1983
)
0.27
"Thirty patients diagnosed as suffering from endogenous depression were entered into a 3-week double-blind trial comparing three times a day dosage of dothiepin with a single night-time dosage in a dosage range of 75 mg to 225 mg per day."( Report on a double-blind comparison of two different regimens of dothiepin (prothiaden).
Boening, J, 1983
)
0.27
" Patients fulfilling defined admission criteria were randomly allocated to treatment with evening dosage of either 50 mg of the sustained release preparation or 75 mg of dothiepin for the first week of the trial."( Clinical trial comparison of a sustained release form of amitriptyline with dothiepin.
Dorman, T, 1980
)
0.26
" The result of the current ongoing clinical trails in the United States with several hundred patients will more precisely define the efficacy, dosage and side effect profile of dothiepin."( An overview of seventeen years of experience with dothiepin in the treatment of depression in Europe.
Claghorn, JL; Goldstein, BJ, 1980
)
0.26
" During the whole study, 63% of the population were treated with 75 mg as daily dosage of dothiepin."( [Action and tolerance of dothiepin hydrochloride (Prothiaden) in depressive states during the evolution of psychotic disorders].
Boudet, A; De Sahb, R; Leutenegger, E; Sechter, D,
)
0.43
" The patients were randomised to receive dothiepin (with dosage increasing to 150 mg/day) or placebo as an aid to withdrawal before benzodiazepine reduction and these drugs were taken for four further weeks before being stopped."( A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms.
Barczak, P; Caplan, R; Cooper, S; Ferguson, B; Hallström, C; Michie, M; Tyrer, P; Tyrer, S, 1996
)
0.29
"), shifted the dose-response relationships to the right for each of the antidepressant agents (dothiepin, amitriptyline, sibutramine, (+)-oxaprotiline and paroxetine)."( The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Gray, AM; Sewell, RD; Spencer, PS, 1998
)
0.3
"There is good evidence for an association between dosulepin and subsequent ischaemic heart disease and for a dose-response relation."( Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care.
Coupland, C; Crown, N; Hammersley, V; Hippisley-Cox, J; Meal, A; Pringle, M; Wynn, A, 2001
)
0.31
" The proposed methods were successfully applied for the determination of dothiepin hydrochloride in bulk powder and in capsule dosage form."( Kinetic spectrophotometric methods for the determination of dothiepin hydrochloride in bulk and in drug formulation.
Taha, EA, 2003
)
0.79
"Three rapid, simple, reproducible and sensitive extractive colorimetric methods (A--C) for assaying dothiepin hydrochloride (I) and risperidone (II) in bulk sample and in dosage forms were investigated."( Extractive colorimetric method for the determination of dothiepin hydrochloride and risperidone in pure and in dosage forms.
Hassan, Wel-S, 2008
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
dothiepin
dothiepin hydrochloride
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency12.58930.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID743255
Smad3Homo sapiens (human)Potency3.54810.00527.809829.0929AID588855
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)3.40000.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)3.40000.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)3.40000.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)3.40000.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)3.40000.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)3.40000.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)3.40000.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)3.40000.00304.11059.8200AID1804127
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)3.40000.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)3.40000.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1346971Human NET (Monoamine transporter subfamily)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID1346037Human H1 receptor (Histamine receptors)1999Cellular and molecular neurobiology, Aug, Volume: 19, Issue:4
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1993Biochemical pharmacology, Jun-09, Volume: 45, Issue:11
Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))1993Biochemical pharmacology, Jun-09, Volume: 45, Issue:11
Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1993Biochemical pharmacology, Jun-09, Volume: 45, Issue:11
Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1993Biochemical pharmacology, Jun-09, Volume: 45, Issue:11
Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics.
AID1346943Human SERT (Monoamine transporter subfamily)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1993Biochemical pharmacology, Jun-09, Volume: 45, Issue:11
Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (271)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990118 (43.54)18.7374
1990's86 (31.73)18.2507
2000's44 (16.24)29.6817
2010's19 (7.01)24.3611
2020's4 (1.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.80 (24.57)
Research Supply Index5.89 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index55.23 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials79 (27.92%)5.53%
Trials0 (0.00%)5.53%
Reviews11 (3.89%)6.00%
Reviews0 (0.00%)6.00%
Case Studies64 (22.61%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other129 (45.58%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]